Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...
Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...
SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
Technology from computing powerhouse Nvidia is already hard at work inside companies at the convergence of technology and biology, including the supercomputer driving Recursion Pharmaceutical’s drug ...
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Recursion Pharmaceuticals ...
AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. Recursion was able to use its artificial intelligence-enabled drug discovery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results